Insulet Corp

PODD: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$467.00QpbcnnWbctmqvn

Insulet Moves Forward With Key Integrations on iOS Phones and Dexcom's G7

Business Strategy and Outlook

With little direct competition in patch pumps, Insulet has been able to convert more users, especially patients on multiple daily injections, to its innovative, tubeless insulin pump. The firm is on the path to meaningful profitability gains.

Sponsor Center